Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For individuals with mmOSA, CRP levels were associated with hypertension risk and insulin resistance among those aged less than 60 years.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...

“For obese individuals with moderate to severe sleep apnea, this new treatment option ... given that loud snoring and gasping for air are primary symptoms,” she said. Dr. William Lu, medical ...

both of which found that Zepbound helps reduce sleep apnea symptoms in some patients by aiding weight loss. Both studies monitored obese adults with moderate to severe sleep apnea over a 52-week ...

The FDA suggests that prescribed users also reduce their calorie intake and increase their exercise The weight loss drug ...